377 related articles for article (PubMed ID: 19918015)
1. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16.
Landman GW; Kleefstra N; van Hateren KJ; Groenier KH; Gans RO; Bilo HJ
Diabetes Care; 2010 Feb; 33(2):322-6. PubMed ID: 19918015
[TBL] [Abstract][Full Text] [Related]
2. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.
Bo S; Ciccone G; Rosato R; Villois P; Appendino G; Ghigo E; Grassi G
Diabetes Obes Metab; 2012 Jan; 14(1):23-9. PubMed ID: 21812892
[TBL] [Abstract][Full Text] [Related]
3. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS
Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242
[TBL] [Abstract][Full Text] [Related]
4. Increased cancer mortality in type 2 diabetes (ZODIAC-3).
Landman GW; Ubink-Veltmaat LJ; Kleefstra N; Kollen BJ; Bilo HJ
Anticancer Res; 2008; 28(2B):1373-5. PubMed ID: 18505082
[TBL] [Abstract][Full Text] [Related]
5. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
6. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
Currie CJ; Poole CD; Gale EA
Diabetologia; 2009 Sep; 52(9):1766-77. PubMed ID: 19572116
[TBL] [Abstract][Full Text] [Related]
7. Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models.
Farmer RE; Ford D; Mathur R; Chaturvedi N; Kaplan R; Smeeth L; Bhaskaran K
Int J Epidemiol; 2019 Apr; 48(2):527-537. PubMed ID: 30753459
[TBL] [Abstract][Full Text] [Related]
8. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
[TBL] [Abstract][Full Text] [Related]
9. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
[TBL] [Abstract][Full Text] [Related]
10. Alanine aminotransferase and mortality in patients with type 2 diabetes (ZODIAC-38).
Deetman PE; Alkhalaf A; Landman GW; Groenier KH; Kootstra-Ros JE; Navis G; Bilo HJ; Kleefstra N; Bakker SJ
Eur J Clin Invest; 2015 Aug; 45(8):807-14. PubMed ID: 26046667
[TBL] [Abstract][Full Text] [Related]
11. Glycaemic control and the risk of mortality in elderly type 2 diabetic patients (ZODIAC-20).
van Hateren KJ; Landman GW; Kleefstra N; Drion I; Groenier KH; Houweling ST; Bilo HJ
Int J Clin Pract; 2011 Apr; 65(4):415-9. PubMed ID: 21401830
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Kooy A; de Jager J; Lehert P; Bets D; Wulffelé MG; Donker AJ; Stehouwer CD
Arch Intern Med; 2009 Mar; 169(6):616-25. PubMed ID: 19307526
[TBL] [Abstract][Full Text] [Related]
13. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
14. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus.
Gosmanova EO; Canada RB; Mangold TA; Rawls WN; Wall BM
Am J Med Sci; 2008 Sep; 336(3):241-7. PubMed ID: 18794619
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
[TBL] [Abstract][Full Text] [Related]
16. Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria.
Konrad K; Datz N; Engelsberger I; Grulich-Henn J; Hoertenhuber T; Knauth B; Meissner T; Wiegand S; Woelfle J; Holl RW;
Pediatr Diabetes; 2015 Nov; 16(7):529-37. PubMed ID: 25131985
[TBL] [Abstract][Full Text] [Related]
17. Early Glycemic Control and Magnitude of HbA
Svensson E; Baggesen LM; Johnsen SP; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Thomsen RW
Diabetes Care; 2017 Jun; 40(6):800-807. PubMed ID: 28404659
[TBL] [Abstract][Full Text] [Related]
18. The relationship between glycaemic control and mortality in patients with type 2 diabetes in general practice (ZODIAC-11).
Landman GW; van Hateren KJ; Kleefstra N; Groenier KH; Gans RO; Bilo HJ
Br J Gen Pract; 2010 Mar; 60(572):172-5. PubMed ID: 20202363
[TBL] [Abstract][Full Text] [Related]
19. Glucose-lowering treatment and clinical results in 163 121 patients with type 2 diabetes: an observational study from the Swedish national diabetes register.
Ekström N; Miftaraj M; Svensson AM; Andersson Sundell K; Cederholm J; Zethelius B; Gudbjörnsdottir S; Eliasson B
Diabetes Obes Metab; 2012 Aug; 14(8):717-26. PubMed ID: 22364580
[TBL] [Abstract][Full Text] [Related]
20. Type 2 diabetes: target HbA1c of about 7%.
Prescrire Int; 2009 Aug; 18(102):177. PubMed ID: 19746575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
